Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma
PHASE1CompletedINTERVENTIONAL
Enrollment
7
Participants
Timeline
Start Date
November 5, 2019
Primary Completion Date
February 14, 2024
Study Completion Date
February 14, 2024
Conditions
Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRichter SyndromeSmall Lymphocytic LymphomaTransformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell LymphomaTransformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaTransformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
DRUG
Duvelisib
Given PO
BIOLOGICAL
Nivolumab
Given IV
Trial Locations (1)
43210
Ohio State University Comprehensive Cancer Center, Columbus
All Listed Sponsors
lead
David Bond, MD
OTHER
NCT03892044 - Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma | Biotech Hunter | Biotech Hunter